Chronic Myelomonocytic Leukemia clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

    open to eligible people ages 18 years and up

    To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)

    San Francisco, California and other locations

Our lead scientists for Chronic Myelomonocytic Leukemia research studies include .

Last updated: